



The University of Sydney
at Westmead Hospital

Australian General Practice Statistics and Classification Centre
Family Medicine Research Centre



BEACH

BETTERING THE EVALUATION AND CARE OF HEALTH

Allopurinol (12 month data)
April 2003 – March 2004

November 2008

Enquiries to: Helena Britt

Telephone: (02) 9845 8151

Explanatory notes for Problem Report

Background

This report represents a summary of the data collected from April 2003 until March 2004 inclusive. It provides information on the prescribing of Allopurinol (CAPS generic code 'M302').

Each year, BEACH collects data from around 1,000 GPs, who each record details about 100 consecutive consultations, thus providing an annual database of approximately 100,000 records.

Summary of BEACH data

BEACH Year	Number of GPs Raw (weighted)	Number of encounters Raw (weighted)	Number of problems managed Raw (weighted)	Number of medications (prescribed, GP supplied, over the counter) Raw (weighted)	Number of prescribed medications Raw (weighted)
April 1998- March 1999	984 (969.0)	98,400 (96,900.9)	145,183 (140,823.7)	107,451 (106,320.0)	91,427 (90,709.9)
April 1999- March 2000	1047 (1048.6)	104,700 (104,856.3)	156,576 (153,857.1)	113,555 (115,431.5)	96,925 (98,371.8)
April 2000- March 2001	999 (993.1)	99,900 (99,307.3)	147,518 (143,528.3)	108,179 (107,399.6)	91,602 (91,647.2)
April 2001- March 2002	983 (969.7)	98,300 (96,972.9)	144,372 (139,091.8)	102,352 (101,349.9)	85,304 (85,332.1)
April 2002- March 2003	1008 (1009.9)	100,800 (100,987.0)	149,976 (146,335.7)	103,289 (104,813.3)	83,755 (85,161.4)
April 2003- March 2004	1000 (1000.0)	100,000 (98,876.7)	150,126 (144,674.0)	103,774 (103,210.1)	85,023 (85,073.4)
April 2004- March 2005	953 (954.0)	95,300 (94,385.8)	141,489 (137,329.9)	95,672 (95,816.3)	77,913 (78,711.1)
April 2005- March 2006	1017 (1017.3)	101,700 (101,993.0)	152,802 (149,087.9)	105,340 (106,492.6)	85,600 (87,543.6)
April 2006- March 2007	930 (930.0)	93,000 (91,804.7)	140,886 (136,333.2)	93,140 (93,193.5)	75,495 (76,430.4)
April 2007- March 2008	953 (953.1)	95,300 (95,897.7)	147,724 (145,078.0)	96,488 (98,439.3)	76,440 (79,051.3)

The participating GPs are randomly selected from the HIC list of active GPs (those who provided more than 375 GP services in the previous quarter). The research instrument used for each consultation is a single page recording form. An example of the recording forms can be found in Appendix 1 of the BEACH annual report, General practice activity in Australia 2006-07 <<http://www.aihw.gov.au/publications/gep/gpaa06-07/gpaa06-07-x03a.pdf>>. The recording form contains the following variables:

- Date of encounter
- Medicare Benefits Schedule (MBS) item number (up to three)/form of payment/indirect encounters (e.g. telephone consults)
- Patient age and sex
- Patient status to practice (new or seen before)
- Health care card status of patient
- Patient post code and ethnic background
- Patient's reasons for encounter (up to three per encounter)
- Diagnoses/problems managed (up to four)
- Status of each problem to the patient (new/old)
- Whether problems are work related
- Medications prescribed (up to four per problem)
- Over the counter medications recommended
- Medications provided by the GP
- Name, strength and regimen of medication
- Number of repeats for medication
- Medication status - new or continued
- Other treatments (up to two per problem)
- Pathology tests ordered (up to five)
- Imaging ordered (up to two)
- Referrals and hospital admissions (up to two).

Statistical Analysis

The confidence interval (CI) is calculated as the rate estimate \pm (1.96 x standard error). The CI is interpreted as “we are 95% confident that the true population value lies between the lower and upper value”. Please note that in some cases, if there were less than three observations (n) in the row, no 95% CIs are provided as data were insufficient to calculate a meaningful estimate. The analysis used procedures in SAS v9.1 that calculate standard errors which adjust for the cluster survey design¹. Keep in mind when reading the report, where BEACH data are reported in a standard set of categories (e.g. types of Medicare claimable encounters), a missing category means there were no occurrences of the event (e.g. home visits missing indicates no home visits were done for this condition/group of conditions). Also, where the most common 30 or 60 cases are listed (e.g. most frequent patient reasons for encounter, table 3.4), only the 30 with the highest frequency of occurrence have been printed. While there may have been other cases with a lower frequency of occurrence, the list has been cut off at 30.

TABLE A: Summary of all medications – allopurinol – Apr03-Mar04

This table provides the overall rated prescription/ GP supply of allopurinol. It includes a count of the total number of prescriptions for allopurinol during the time period, the prescription/supply rate for each generic within this group of drugs, and a breakdown of the rate at which the participating GPs recorded the script as a generic name and the relative rate of prescription of each of the product names for this generic. The prescribing rates are presented in terms of the rate per 100 BEACH encounters, the rate per 100 problems managed and the percentage of all medications that is accounted for by this medication. If the selected medication is a class of drugs then the percent of this class that is accounted for by each generic or specific product is listed in the column titled “% of allopurinol”. The “% generic” column shows the percentage of a generic accounted for by each specific product.

The “national annual estimated meds” gives the estimated number of GP contacts where the specified medication was prescribed/supplied/advised in the selected year across Australia. It is calculated as [*the number of specified medications prescribed/supplied/advised (n) / the total number of recorded encounters within the specified study period*] X *the number of general practice consultations claimed from Medicare in the specified year*. If you have requested encounters for a selected patient characteristic/s (e.g. sex, age, state) this column will be restricted to the national annual estimate of consultations with those selected patient characteristic/s.

¹ SAS Institute. SAS/STAT® User's guide, Version 9.1. Cary, NC: SAS Institute Inc, 2003.

The table below lists the number of non-specialist GP Medicare services for each specified BEACH year (April-March)². If your report is based on multiple BEACH years (e.g. 2003-04 to 2005-06) the rate has been extrapolated to the average annual GP consultations over the multiple years E.g. (96,300,000+ 98,200,000 + 101,100,000) / 3.

	BEACH year	Annual GP consultations[^]
1	1998-99	102,600,000
2	1999-00	101,500,000
3	2000-01	100,600,000
4	2001-02	99,900,000
5	2002-03	96,900,000
6	2003-04	96,300,000
7	2004-05	98,200,000
8	2005-06	101,100,000
9	2006-07	103,400,000
10	2007-08	109,500,000
11	2008-09	109,500,000 *

[^]Annual GP consultations are rounded to the nearest 100,000.

Available online at : <http://www.health.gov.au/internet/main/publishing.nsf/Content/medstat-mar08-tables-b>

Then select Table b1 – Number of services

* Estimation as data is not yet available

TABLE B: Summary of ‘new’ medications – allopurinol – Apr03-Mar04

The above analysis is repeated for the allopurinol which are classified as ‘new’. A *new medication* is one that is being prescribed/supplied/advised for the management of this problem in this patient for the first time.

TABLE C: Summary of ‘continued’ medications – allopurinol – Apr03-Mar04

The above analysis is repeated for the allopurinol which are classified as ‘continued’. A *continued medication* is one that is being prescribed/supplied/advised as a continuation or a repeat of a previous therapy for this problem.

² Medicare Australia. 2006. Medicare Benefits Schedule (MBS) statistics reports. <http://www.health.gov.au/internet/main/publishing.nsf/Content/medstat-mar08-tables-b>.

SECTION 1: SUMMARY OF ENCOUNTERS

TABLE 1a: Type of encounter – allopurinol – Apr03-Mar04

Definitions of the categories are as follows:

Encounter (enc): Any professional interchange between a patient and a GP.

Direct encounters: Encounters where there is a face-to-face meeting of the patient and the GP.

No charge: Encounters where no fee (Medicare bulk billing or other) is received for the service provided.

MBS items by GPs: Encounters claimable through the MBS. The following groups are claimable through the relevant MBS item numbers.

Short surgery consults: (Level A) A short encounter which requires limited examination and management.

Standard surgery consults: (Level B) An encounter of less than 20 minutes duration, which requires an examination of the patient and an implementation of a management plan in relation to at least one of the problems.

Long surgery consults: (Level C) An encounter with duration between 20 and 40 minutes, which involves taking a detailed history and implementing a management plan for at least one of the problems.

Prolonged surgery consults: (Level D) An encounter with a duration of more than 40 minutes, which involves taking an exhaustive history, a comprehensive examination, the arrangement of necessary investigations and implementing a management plan for at least one of the problems.

Home visits: Encounters that take place in the patient's home and a MBS home visit item number(s) are recorded.

Hospital: Encounters that take place with a patient in a hospital setting, and a MBS hospital item number(s) are recorded.

Residential aged care facility: Encounters that take place in a residential aged care facility (RACF) and an MBS RACF item number is recorded.

Case conferences: Encounters that are covered by a MBS item number for a case conference.

Chronic disease management: Encounters that are covered by a MBS chronic disease management item number(s).

GP mental health care: Encounters that are covered by a MBS GP mental health care plan item number(s).

Health assessments: Encounters that are covered by a MBS item number for a health assessment.

Incentive payments: Encounters where MBS incentive payment items are recorded.

Other items: Medicare item numbers that do not identify the place of encounter and are not covered by any of the above item numbers.

Worker's compensation: Encounters claimable through Worker's Compensation.

Other paid (hospital, state etc): All other direct services covered by other funding services e.g. insurance, employer, state health dept, hospitals, etc.

Direct encounters with practice nurse item only: Encounters where a practice nurse item number was the only item number recorded though the patient was said to have been seen by the GP.

Indirect encounters: Encounters where there is no face-to-face meeting between the patient and the GP but a service is provided (e.g. prescription, referral).

Indirect encounters with practice nurse item only: Encounters where a practice nurse item number was the only item number recorded, and the patient was said *not* to have been seen by the GP.

Unspecified practice nurse item only: Encounters where a practice nurse item number was the only item number recorded, and it is unknown whether the patient was/wasn't seen by the GP.

TABLE 1a 2: Summary of data base: services – allopurinol – Apr03-Mar04

This table will only be valid if **all** of your data are from the period April 2005 onwards. If your data are based on years that cross April 2005, this table is not valid. This is because, prior to April 2005 only one item number could be recorded. From April 2005 onwards, up to three Medicare item numbers could be recorded on an encounter form. The denominator for the column titled "per 100 encs" is all encounters (from table 1a). This table is useful when allocating direct costs against management of a selected problem.

TABLE 1b: Summary of database: morbidity and management – allopurinol – Apr03-Mar04

This table describes the characteristics of the problems and medications that are included in this report. Number of observations (n), rate per 100 problems, and 95% confidence intervals (CI) are provided for each data point.

General practitioners is the number of GPs who recorded encounters that are included in this report (i.e. those who prescribed/supplied/advised allopurinol within the specified data period).

Problem managed: A formal statement of the providers' understanding of a health problem presented by the patient, family or community. It can be described in terms of a disease, symptom/complaint, social problem or ill-defined condition managed at the encounter (up to four per encounter).

New problems: The first presentation of a problem, including the first presentation of a recurrence of a previously resolved problem but excluding the presentation of a problem first assessed by another provider.

Old problems: A previously assessed problem that requires ongoing care. Includes follow-up for a problem or an initial presentation of a problem previously assessed by another provider.

Work related: A problem that is viewed as having resulted or been significantly exacerbated from a work-related activity or workplace exposures.

Medications: The total number of the selected medication/s that are prescribed, advised for over-the-counter (OTC) purchase or provided from the GP's own supplies (GP supplied). Up to four medications can be recorded for each problem.

Prescribed: The total number of the selected medication/s that were prescribed by the GP.

GP supplied: The total number of the selected medication/s that were provided from the practice supplies e.g. sample or vaccine.

Advised OTC: The total number of the selected medication/s that were advised to be purchased over-the-counter i.e. an S2 or S3 product.

New: A medication that is prescribed/supplied/advised is being used for the management of the problem for the first time.

Continued: A medication that is prescribed/supplied/advised as a continuation or a repeat of previous therapy for the problem.

SECTION 2: GENERAL PRACTITIONERS

Tables 2.1 and 2.2 display the characteristics of the GPs who prescribed/supplied/advised allopurinol at least once.

TABLE 2.1: General practitioners: age by sex – allopurinol – Apr03-Mar04

This table displays the age-sex distribution of the GPs who were included in this analysis. These data were collected from the GP Profile Questionnaire which is completed by all GPs participating in the BEACH project (see Appendix 2 in BEACH annual report, General practice activity in Australia 2006-07, <<http://www.aihw.gov.au/publications/gep/gpaa06-07/gpaa06-07-x03a.pdf>>).

TABLE 2.2: GP characteristics – allopurinol – Apr03-Mar04

This table displays the characteristics of the GPs, collected from the GP Profile Questionnaire. Definitions of the categories are as follows:

Years in general practice: The number of years the GP has been in general practice.

Sessions: The number of consulting sessions per week for each GP (1 session = approx. 4 hours e.g. a morning session).

Size of practice: The number of GPs in the participating GPs main practice (including the participating GP).

Practice state: The state which the GPs main practice is in.

RRMA of main practice (Rural, Remote & Metropolitan Area Classification) classifies the location of the practice to one of 7 categories <www.ruraldoc.com.au>.

ASGC of main practice (Australian Standard Geographical Classification) classifies the location of the practice to one of 5 categories <www.abs.gov.au>.

Country of Graduation: The GPs reported country of graduation.

>50% consults NESB: (non-English speaking background) the GPs assessment of the proportion of their consultations conducted in a language other than English.

Hold FRACGP is whether the participating GP is a Fellow of the Royal Australian College of General Practitioners.

Practice accredited is whether the practice is accredited.

SECTION 3: PATIENT CHARACTERISTICS

TABLE 3.1: Summary of database: patients – allopurinol – Apr03-Mar04

This table describes the characteristics of the patients who received the selected medication at their encounter. Number of observations (n), rate per 100 problems, and 95% confidence intervals (CI) are provided for each data point.

Sex and age distributions are provided. The age groupings correspond with significant trends in GP service use.

HCC card: Encounters with patients who hold an Australian Government health care card (HCC).

VA card: Encounters with Veteran’s Affair card holders (not necessarily charged through VA).

NESB: Encounters with patients whose primary language spoken at home is not English (non-English speaking background).

Aboriginal only: Patients who identify themselves as being Aboriginal and not Torres Strait Islander.

Torres Strait Islander only: Patients who identify themselves as being Torres Strait Islander and not Aboriginal.

Aboriginal & Torres Strait Islander: Patients who identify themselves as being both an Aboriginal and a Torres Strait Islander.

Aboriginal and/or TSI: Patients who are Aboriginal or Torres Strait Islanders, or both.

New to practice: Patients who had not been seen previously in this practice.

Seen previously: Patients who had been seen previously in this practice.

State/territory: The patients’ state/territory is provided, based on the postcode reported by the patient.

RRMA (Rural, Remote & Metropolitan Areas classification) classifies the patients’ locations to one of 7 categories <www.ruraldoc.com.au>.

ASGC (Australian Standard Geographical Classification) classifies the patients’ locations to one of 5 categories <www.abs.gov.au>.

TABLE 3.2: Age by gender of patient at encounter – allopurinol – Apr03-Mar04

This table displays the age-sex distribution of the patients that have been included in this analysis.

TABLE 3.3: Reasons for encounters (RFEs) – ICPC chapter – allopurinol – Apr03-Mar04

Reasons for encounter (RFE) reflect the patients’ expressed demand for care as perceived and recorded by the GP. Up to three RFEs can be recorded at each encounter. A RFE is not directly linked to a problem managed. This table gives the number of RFEs recorded for encounters where the selected medication was prescribed/supplied/advised. RFEs have been grouped using ICPC-2 PLUS chapter headings which correspond approximately to the main body systems with additional chapters for social and psychological problems. Problems which cross multiple body systems are grouped together as “General & unspecified”.

Each RFE is coded using ICPC-2 PLUS and classified to ICPC-2. There are seventeen chapters in ICPC-2 which are mainly based on body systems. Details on these chapters can be found at <www.fmrc.org.au/icpc2/tech.htm>.

This table shows the distribution of RFEs by ICPC-2 chapter at the encounters where allopurinol were prescribed/supplied/advised.

TABLE 3.4: Most frequent patient reasons for encounter (RFEs) – allopurinol – Apr03-Mar04

This table shows the 30 most common RFEs recorded at the encounters where allopurinol were prescribed/supplied/advised. The RFE label is the individual ICPC rubric label unless denoted by *, which indicates a grouping of multiple ICPC rubrics under the same RFE (concept) label. Number of observations (n), % of total RFEs, rate per 100 encounters and 95% CIs are provided for each data point.

SECTION 4: ALL MEDICATIONS

TABLE 4.1: Medication source – allopurinol – Apr03-Mar04

This table displays the method by which the medication was provided (i.e. prescribed by the GP, supplied by the GP, or advised for OTC purchase. Refer to notes on Table 1b for definitions of prescribed/supplied/advised medications). Medication source is of greatest interest where the selected medication can be either prescribed or advised (e.g. paracetamol). The data are presented in three levels –

Total prescribed/supplied/advised allopurinol

Generic allopurinol

Individual product recorded by the GP

At each level, the medication is expressed as the number of observations (n), as a percentage of the total allopurinol that were prescribed/supplied/advised, and upper and lower CIs. The right section of the table shows the number that was prescribed/supplied/advised, and the percentage of each medication.

TABLE 4.2: Medication status – allopurinol – Apr03-Mar04

This table displays the status of each medication as being either new or continued (refer to notes on Table 1b for definitions of new and continued), and these figures are expressed as a percentage of the total allopurinol. The first three columns also appear in Table A and notes for these are provided in the explanatory notes for Table A. The right section of the table shows the number that was new/continued, and the percentage of each medication.

TABLE 4.3.1: Prescribed regimen – allopurinol (generic level) – Apr03-Mar04

The prescribed regimen of the selected medication is presented in this table at generic level. “Prescribed regimen” includes prescribed, supplied and advised medications. The prescribed dose, units, quantity and frequency (quantity + frequency usually = number of times per day) are provided for each medication. The column labelled “% of generic group” represents the percentage of a generic accounted for by the medication with a particular regimen. It is calculated as *[the number of each generic with an exact regimen / the total number of a specific generic] X 100*.

TABLE 4.3.2: Prescribed regimen – allopurinol (product level) – Apr03-Mar04

The prescribed regimen of the selected medication is presented in this table at product level. Explanations for the columns parallel those in Table 4.3.2.

TABLE 4.4.1: Prescribed daily dose – allopurinol (generic level) – Apr03-Mar04

Medications that are prescribed/supplied/advised by the GP, for which complete regimen and dosage (in micrograms, milligrams or grams) information are recorded, are included in the calculation of the prescribed daily dose (PDD). The number of medications (n) and the prescribed daily doses for each generic medication are shown. Complete dosage and regimen information are required for calculation of PDD. The column labelled “% of generic group” is calculated as: *[the number of each generic with this PDD/the total number of each generic with a valid PDD] X 100*.

TABLE 4.4.2: Prescribed daily dose – allopurinol (product level) – Apr03-Mar04

The prescribed daily dose of the selected medication is presented in this table at product level. Explanations for the columns parallel those in Table 4.4.1.

TABLE 4.5: Average prescribed daily dose – allopurinol – Apr03-Mar04

This table provides the mean PDD, median PDD, minimum and maximum PDD for the selected medication, at generic and product level. “Average prescribed daily dose” includes prescribed, supplied and advised medications. Note that the median is often a more reliable measure of central tendency than the mean, which is influenced by outliers.

TABLE 4.6: Average number of repeats – allopurinol – Apr03-Mar04

For each problem managed with the selected medication this table provides the mean, median, minimum and maximum number of repeats, at generic and product level. Again note that the median is often a more reliable measure of central tendency than the average which is influenced by outliers.

SECTION 5: NEW MEDICATIONS

TABLE 5.1: Medication source – ‘new’ allopurinol – Apr03-Mar04

This table displays the method by which the medication was provided (i.e. prescribed by the GP, supplied by the GP, or advised for OTC purchase (similar to Table 4.1) for encounters where the medication was classified as ‘new’ (see definition Table 1b).

TABLE 5.2: Medication status – ‘new’ allopurinol – Apr03-Mar04

This table displays the status of each medication as being either new or continued (similar to Table 4.2) for encounters where the medication was classified as ‘new’ (see definition Table 1b).

TABLE 5.3.1: Prescribed regimen – ‘new’ allopurinol (generic level) – Apr03-Mar04

This table displays the prescribed regimen of the selected medication at generic level (similar to Table 4.3.1) for encounters where the medication was classified as ‘new’ (see definition Table 1b).

TABLE 5.3.2: Prescribed regimen – ‘new’ allopurinol (product level) – Apr03-Mar04

This table displays the prescribed regimen of the selected medication at product level (similar to Table 4.3.2) for encounters where the medication was classified as ‘new’ (see definition Table 1b).

TABLE 5.4.1: Prescribed daily dose – ‘new’ allopurinol (generic level) – Apr03-Mar04

This table displays the prescribed daily dose of the selected medication at generic level (similar to Table 4.4.1) for encounters where the medication was classified as ‘new’ (see definition Table 1b).

TABLE 5.4.2: Prescribed daily dose – ‘new’ allopurinol (product level) – Apr03-Mar04

This table displays the prescribed daily dose of the selected medication at product level (similar to Table 4.4.2) for encounters where the medication was classified as ‘new’ (see definition Table 1b).

TABLE 5.5: Average prescribed daily dose – ‘new’ allopurinol – Apr03-Mar04

This table displays the average prescribed daily dose of the selected medication, at generic and product level (similar to Table 4.5) for encounters where the medication was classified as ‘new’ (see definition Table 1b).

TABLE 5.6: Average number of repeats – ‘new’ allopurinol – Apr03-Mar04

This table displays the average number of repeats of the selected medication, at generic and product level (similar to Table 4.6) for encounters where the medication was classified as ‘new’ (see definition Table 1b).

SECTION 6: CONTINUED MEDICATIONS

TABLE 6.1: Medication source – ‘continued’ allopurinol – Apr03-Mar04

This table displays the method by which the medication was provided (i.e. prescribed by the GP, supplied by the GP, or advised for OTC purchase (similar to Table 4.1) for encounters where the medication was classified as ‘continued’ (see definition Table 1b).

TABLE 6.2: Medication status – ‘continued’ allopurinol – Apr03-Mar04

This table displays the status of each medication as being either new or continued (similar to Table 4.2) for encounters where the medication was classified as ‘continued’ (see definition Table 1b).

TABLE 6.3.1: Prescribed regimen – ‘continued’ allopurinol (generic level) – Apr03-Mar04

This table displays the prescribed regimen of the selected medication at generic level (similar to Table 4.3.1) for encounters where the medication was classified as ‘continued’ (see definition Table 1b).

TABLE 6.3.2: Prescribed regimen – ‘continued’ allopurinol (product level) – Apr03-Mar04

This table displays the prescribed regimen of the selected medication at product level (similar to Table 4.3.2) for encounters where the medication was classified as ‘continued’ (see definition Table 1b).

TABLE 6.4.1: Prescribed daily dose – ‘continued’ allopurinol (generic level) – Apr03-Mar04

This table displays the prescribed daily dose of the selected medication at generic level (similar to Table 4.4.1) for encounters where the medication was classified as ‘continued’ (see definition Table 1b).

TABLE 6.4.2: Prescribed daily dose – ‘continued’ allopurinol (product level) – Apr03-Mar04

This table displays the prescribed daily dose of the selected medication at product level (similar to Table 4.4.2) for encounters where the medication was classified as ‘continued’ (see definition Table 1b).

TABLE 6.5: Average prescribed daily dose – ‘continued’ allopurinol – Apr03-Mar04

This table displays the average prescribed daily dose of the selected medication, at generic and product level (similar to Table 4.5) for encounters where the medication was classified as ‘continued’ (see definition Table 1b).

TABLE 6.6: Average number of repeats – ‘continued’ allopurinol – Apr03-Mar04

This table displays the average number of repeats of the selected medication, at generic and product level (similar to Table 4.6) for encounters where the medication was classified as ‘continued’ (see definition Table 1b).

SECTION 7: PROBLEMS MANAGED**TABLE 7.1.1: Problems managed – ICPC chapter – allopurinol – Apr03-Mar04**

This table described the distribution, by ICPC chapter, of all problems (includes all diagnoses, diseases, ill-defined conditions and complaints) for which the GP prescribed/supplied/advised the selected medication at the encounter. The column labelled “% of GPs” includes the proportion of all GPs within the data period who prescribed/supplied/advised at least one of the selected medications to manage the specific problem. “% of specific problem” includes the proportion of the specific problem managed with at least one of the selected medications at the encounter. Number of problems (n), % of allopurinol problems, and 95% confidence interval (CI) are also provided for each data point.

TABLE 7.1.2: Problems managed – allopurinol – Apr03-Mar04

This table described the distribution, by the individual ICPC rubric label, of all problems (includes all diagnoses, diseases, ill-defined conditions and complaints) for which the GP prescribed/supplied/advised the selected medication at the encounter. The asterisk (*) indicates a grouping of multiple ICPC rubrics under the same problem (concept) label, e.g. “Hypertension*” groups the ICPC rubrics of Hypertension Uncomplicated (K86) and Hypertension Complicated (K87). (See Appendix 5 of the BEACH annual report, General practice activity in Australia 2005-06, <<http://www.aihw.gov.au/publications/gep/gpaa05-06/gpaa05-06-x03.pdf>>).

The column labelled “% of GPs” includes the proportion of all GPs within the data period who prescribed/supplied/advised at least one of the selected medications to manage the specific problem. “% of specific problem” includes the proportion of the specific problem managed with at least one of the selected medications at the encounter. Number of problems (n), % of allopurinol problems, and 95% confidence interval (CI) are also provided for each data point.

TABLE 7.2: Medication source by individual problem managed – allopurinol – Apr03-Mar04

This table displays the method by which the medication was provided (similar to Table 4.1) by the problem managed. The right section of the table shows the number that was prescribed/supplied/advised, and the percentage of each problem (refer to notes on Table 1b for definitions of prescribed/supplied/advised medications).

TABLE 7.3: Medication status by individual problem managed – allopurinol – Apr03-Mar04

This table displays the status of the selected medication (similar to Table 4.2) by the problem managed. The right section of the table shows the number that was new/continued, and the percentage of each problem (refer to notes on Table 1b for definitions).

TABLE 7.4: Prescribed regimen by individual problem managed for each generic – allopurinol – Apr03-Mar04

The prescribed regimen of the selected medication is presented for each of the problems for which the selected medication was prescribed/supplied/advised (similar to Table 4.3.1).

TABLE 7.5: Prescribed daily dose by individual problem managed for each generic – allopurinol – Apr03-Mar04

For each problem managed with the selected medication, this table provides the prescribed daily dose recorded by the GPs. For further notes refer to Table 4.4.1.

TABLE 7.6: Average prescribed daily dose by individual problem managed for each generic – allopurinol – Apr03-Mar04

For each problem managed with the selected medication, this table provides the mean, median, minimum and maximum PDD recorded by the GPs. For further notes refer to Table 4.5.

TABLE 7.7: Average number of repeats by individual problem managed – allopurinol – Apr03-Mar04

For each problem managed with the selected medication this table provides the mean, median, minimum and maximum number of repeats recorded by the GPs. For further notes refer to Table 4.6.

BEACH Survey Report - Analysis date: 03NOV08

Table A: Summary of all medications - Allopurinol Apr03-Mar04

Generic	Product	n	Rate per			Rate per			% of all	% of Allopurinol	% of generic	National annual estimated meds	Lower 95% CI	Upper 95% CI
			100 all encs	Lower 95% CI	Upper 95% CI	100 probs	% of all meds							
Total Allopurinol		356	0.36	0.31	0.40	0.24	0.34	.	.		342800	300100	385600	
Allopurinol		356	0.36	0.31	0.40	0.24	0.34	100.00	.		342800	300100	385600	
	Allopurinol NOS	41	0.04	0.03	0.05	0.03	0.04	11.52	11.52		39500	27000	51900	
	Allopurinol capsules 100 mg	2	0.00	.	.	0.00	0.00	0.56	0.56		1900	.	.	
	Allopurinol capsules 300 mg	9	0.01	0.00	0.02	0.01	0.01	2.53	2.53		8700	2400	14900	
	Allopurinol tablets 100 mg	5	0.01	0.00	0.01	0.00	0.00	1.40	1.40		4800	600	9000	
	Allopurinol tablets 300 mg	8	0.01	0.00	0.01	0.01	0.01	2.25	2.25		7700	1200	14200	
	Progout NOS	4	0.00	0.00	0.01	0.00	0.00	1.12	1.12		3900	100	7600	
	Progout tablets 100 mg	20	0.02	0.01	0.03	0.01	0.02	5.62	5.62		19300	10500	28000	
	Progout tablets 300 mg	58	0.06	0.04	0.07	0.04	0.06	16.29	16.29		55900	40900	70800	
	Zyloprim NOS	3	0.00	0.00	0.01	0.00	0.00	0.84	0.84		2900	0	6200	
	Zyloprim tablets 100 mg	64	0.06	0.05	0.08	0.04	0.06	17.98	17.98		61600	45400	77900	
	Zyloprim tablets 300 mg	142	0.14	0.11	0.17	0.09	0.14	39.89	39.89		136700	110200	163300	

Refer to explanatory notes for the base used in calculation of national annual estimated medications, and the number of estimated medications is rounded to the nearest 100.

The denominators used to calculate column labelled 'Rate per 100 all encs' and 'Rate per 100 probs' are 100000 and 150126 respectively.

BEACH Survey Report - Analysis date: 03NOV08

Table B: Summary of 'new' medications - Allopurinol Apr03-Mar04

Generic	Product	n	Rate per			Rate per			% of all meds	% of Allopurinol	% of generic	National annual estimated meds	Lower 95% CI	Upper 95% CI
			100 all encs	Lower 95% CI	Upper 95% CI	100 probs	Lower 95% CI	Upper 95% CI						
Total Allopurinol		48	0.05	0.03	0.06	0.03	0.05	.	.		46200	32900	59600	
Allopurinol		48	0.05	0.03	0.06	0.03	0.05	100.00	.		46200	32900	59600	
	Allopurinol NOS	9	0.01	0.00	0.01	0.01	0.01	18.75	18.75		8700	3000	14300	
	Allopurinol capsules 300 mg	1	0.00	.	.	0.00	0.00	2.08	2.08		1000	.	.	
	Allopurinol tablets 100 mg	1	0.00	.	.	0.00	0.00	2.08	2.08		1000	.	.	
	Allopurinol tablets 300 mg	1	0.00	.	.	0.00	0.00	2.08	2.08		1000	.	.	
	Progout NOS	1	0.00	.	.	0.00	0.00	2.08	2.08		1000	.	.	
	Progout tablets 100 mg	2	0.00	.	.	0.00	0.00	4.17	4.17		1900	.	.	
	Progout tablets 300 mg	4	0.00	0.00	0.01	0.00	0.00	8.33	8.33		3900	100	7600	
	Zyloprim tablets 100 mg	18	0.02	0.01	0.03	0.01	0.02	37.50	37.50		17300	9400	25300	
	Zyloprim tablets 300 mg	11	0.01	0.00	0.02	0.01	0.01	22.92	22.92		10600	4400	16800	

Refer to explanatory notes for the base used in calculation of national annual estimated medications,
and the number of estimated medications is rounded to the nearest 100.

The denominators used to calculate column labelled 'Rate per 100 all encs' and 'Rate per 100 probs' are 100000 and 150126 respectively.

BEACH Survey Report - Analysis date: 03NOV08

Table C: Summary 'continued' medications - Allopurinol Apr03-Mar04

Generic	Product	n	Rate per			Rate per			% of all	% of Allopurinol	% of generic	National annual estimated meds	Lower 95% CI	Upper 95% CI
			100 all encs	Lower 95% CI	Upper 95% CI	100 probs	% of all meds							
Total Allopurinol		308	0.31	0.27	0.35	0.21	0.30	.	.		296600	256900	336300	
		
Allopurinol		308	0.31	0.27	0.35	0.21	0.30	100.00	.		296600	256900	336300	
	Allopurinol NOS	32	0.03	0.02	0.04	0.02	0.03	10.39	10.39		30800	19600	42000	
	Allopurinol capsules 100 mg	2	0.00	.	.	0.00	0.00	0.65	0.65		1900	.	.	
	Allopurinol capsules 300 mg	8	0.01	0.00	0.01	0.01	0.01	2.60	2.60		7700	1700	13700	
	Allopurinol tablets 100 mg	4	0.00	0.00	0.01	0.00	0.00	1.30	1.30		3900	100	7600	
	Allopurinol tablets 300 mg	7	0.01	0.00	0.01	0.00	0.01	2.27	2.27		6700	1100	12400	
	Progout NOS	3	0.00	0.00	0.01	0.00	0.00	0.97	0.97		2900	0	6200	
	Progout tablets 100 mg	18	0.02	0.01	0.03	0.01	0.02	5.84	5.84		17300	9400	25300	
	Progout tablets 300 mg	54	0.05	0.04	0.07	0.04	0.05	17.53	17.53		52000	37500	66500	
	Zyloprim NOS	3	0.00	0.00	0.01	0.00	0.00	0.97	0.97		2900	0	6200	
	Zyloprim tablets 100 mg	46	0.05	0.03	0.06	0.03	0.04	14.94	14.94		44300	30400	58200	
	Zyloprim tablets 300 mg	131	0.13	0.10	0.16	0.09	0.13	42.53	42.53		126200	100500	151800	

Refer to explanatory notes for the base used in calculation of national annual estimated medications, and the number of estimated medications is rounded to the nearest 100.

Note: The 'continued' medications include medications specified as 'continued' and medications with missing status, assumed to be 'continued'.

The denominators used to calculate column labelled 'Rate per 100 all encs' and 'Rate per 100 probs' are 100000 and 150126 respectively.

BEACH Survey Report - Analysis date: 03NOV08

Table 1a: Type of encounter - Allopurinol Apr03-Mar04

Data	n	%	Lower 95% CI	Upper 95% CI
General practitioners	265	.	.	.
Encounters	355	.	.	.
Direct encounters	320	97.56	95.9	99.2
No charge	1	0.30	0.0	0.9
MBS items by GPs	316	96.34	94.1	98.6
- Short surgery consults	4	1.22	0.0	2.4
- Standard surgery consults	258	78.66	73.8	83.5
- Long surgery consults	41	12.50	8.7	16.3
- Home visits	2	0.61	0.0	1.5
- Hospital	1	0.30	0.0	0.9
- Residential aged care facility	5	1.52	0.2	2.9
- Chronic disease management ite	1	0.30	0.0	0.9
- Other items	4	1.22	0.0	2.4
Worker's compensation	1	0.30	0.0	0.9
Other paid (hospital, state etc)	2	0.61	0.0	1.5
Indirect encounters	8	2.44	0.8	4.1
Missing	27	.	.	.

The indirect encounters with item numbers (eg: chronic disease management item or case conference item) are counted under both MBS items by GPs and indirect encounters. Therefore, the number of no charge, medicare paid, worker's compensation and other paid do not always add up to the number of direct encounters.

During the BEACH study period April 1998 to March 2005, GPs were instructed to record the lowest Medicare item number (e.g.: an A1 item number) if multiple item numbers applied.

From April 2005 onwards, multiple Medicare item numbers (up to 3) could be recorded on an encounter form. The lowest item in the encounter was selected and analysed in this table. This provides comparable results to those reported before April 2005.

BEACH Survey Report - Analysis date: 03NOV08

Table 1b: Summary of database: morbidity and management - Allopurinol Apr03-Mar04

Data	n	Per 100 probs	Lower 95% CI	Upper 95% CI
General practitioners	265	.	.	.
Encounters	355	.	.	.
Reasons for encounter	640	.	.	.
Problems managed	355	.	.	.
- New problems	31	8.73	5.67	11.79
- Old problems	324	91.27	88.21	94.33
Medications	356	100.28	99.70	100.80
- Prescribed	351	98.87	97.50	100.20
- GP supplied	5	1.41	0.20	2.60
- Advised OTC	0	0.00	.	.
- New	48	13.52	9.90	17.20
- Continued	308	86.76	83.10	90.50

Table 2.1: General practitioners: age by sex - Allopurinol Apr03-Mar04

The FREQ Procedure

Table of gpage by gpsex

gpage(GP age)	gpsex(GP sex)		
Frequency	Male	Female	Total
Percent			
Row Pct			
Col Pct			
< 35 years	6	2	8
	2.26	0.75	3.02
	75.00	25.00	
	2.86	3.64	
35-44 years	42	16	58
	15.85	6.04	21.89
	72.41	27.59	
	20.00	29.09	
45-54 years	63	23	86
	23.77	8.68	32.45
	73.26	26.74	
	30.00	41.82	
55+ years	99	14	113
	37.36	5.28	42.64
	87.61	12.39	
	47.14	25.45	
Total	210	55	265
	79.25	20.75	100.00

BEACH Survey Report - Analysis date: 03NOV08

Table 2.2: GP characteristics - Allopurinol Apr03-Mar04

Data	n	%
Years in general practice	.	.
<2 years	1.0	0.4
2-5 years	10.0	3.8
6-10 years	18.0	6.8
11-19 years	67.0	25.5
20+ years	167.0	63.5
Missing	2.0	.
Sessions	.	.
< 5 per week	33.0	12.5
6-10 per week	193.0	73.4
11+ per week	37.0	14.1
Missing	2.0	.
Size of practice	.	.
Solo GP	35.0	13.3
2-4 GPs	110.0	41.8
5+ GPs	118.0	44.9
Missing	2.0	.
Practice state	.	.
ACT	7.0	2.7
NSW	86.0	32.7
VIC	62.0	23.6
QLD	52.0	19.8
SA	21.0	8.0
WA	29.0	11.0
TAS	5.0	1.9
NT	1.0	0.4
Missing	2.0	.
RRMA of main practice	.	.
Unknown	2.0	0.8
Capital	145.0	54.7
Oth Met	17.0	6.4
Lge Rur	25.0	9.4
Sm Rur	22.0	8.3
Oth Rur	46.0	17.4
Rem Cen	3.0	1.1

BEACH Survey Report - Analysis date: 03NOV08

Table 2.2: GP characteristics - Allopurinol Apr03-Mar04

Data	n	%
Oth Rem, Offsh	5.0	1.9
ASGC of main practice	.	.
Major Cities	160.0	60.8
Inner Regional	61.0	23.2
Outer Regional	35.0	13.3
Remote	6.0	2.3
Very Remote	1.0	0.4
Missing	2.0	.
Country of graduation	.	.
Australia	190.0	71.7
New Zealand	4.0	1.5
Asia	37.0	14.0
UK/Ireland	17.0	6.4
America	1.0	0.4
Europe	3.0	1.1
Africa	11.0	4.2
Pacific	2.0	0.8
> 50% consults NESB	.	.
Yes	2.0	0.8
No	263.0	99.2
Hold FRACGP	.	.
Yes	80.0	30.4
No	183.0	69.6
Missing	2.0	.
Practice Accredited	.	.
Yes	213.0	81.3
No	49.0	18.7
Missing	3.0	.
	.	.

BEACH Survey Report - Analysis date: 03NOV08

Table 3.1: Summary of database: patients - Allopurinol Apr03-Mar04

Data	n	%	Lower 95% CI	Upper 95% CI
Patients	355	.	.	.
- Males	285	80.97	76.8	85.1
- Females	67	19.03	14.9	23.2
- Missing sex	3	.	.	.
- 15-24 years	2	0.57	0.0	1.3
- 25-44 years	36	10.20	6.9	13.5
- 45-64 years	144	40.79	35.6	45.9
- 65-74 years	83	23.51	19.0	28.0
- 75+ years	88	24.93	20.3	29.5
- Missing age	2	.	.	.
- HCC card	166	50.61	44.5	56.7
- VA card	22	6.81	4.1	9.6
- NESB	11	3.41	1.2	5.6
- Aboriginal only	7	1.97	0.5	3.4
- Torres Strait Islander only	1	0.28	0.0	0.8
- Aboriginal and/or TSI	8	2.25	0.7	3.8
- New to practice	7	2.04	0.5	3.5
- Seen previously	336	97.96	96.5	99.5
- Missing status	12	.	.	.
- ACT	6	1.72	0.3	3.1
- NSW	126	36.21	29.2	43.2
- VIC	70	20.11	15.1	25.1
- QLD	73	20.98	15.2	26.8
- SA	31	8.91	5.0	12.8
- WA	36	10.34	6.3	14.4
- TAS	5	1.44	0.2	2.7
- NT	1	0.29	0.0	0.9
- Missing state	7	.	.	.
RRMA- Capital	168	48.41	41.5	55.3
- Other Metro	28	8.07	2.9	13.2
- Large Rural	29	8.36	5.0	11.7
- Small Rural	32	9.22	5.2	13.3

BEACH Survey Report - Analysis date: 03NOV08

Table 3.1: Summary of database: patients - Allopurinol Apr03-Mar04

Data	n	%	Lower 95% CI	Upper 95% CI
- Other Rural	78	22.48	16.8	28.1
- Remote Central	5	1.44	0.0	3.3
- Other remote, Offshore	7	2.02	0.1	3.9
- Missing rрма	8	.	.	.
.
ASGC- Major Cities	196	56.48	49.7	63.2
- Inner Regional	88	25.36	19.6	31.1
- Outer Regional	54	15.56	10.8	20.3
- Remote	8	2.31	0.2	4.4
- Very Remote	1	0.29	0.0	0.9
- Missing ASGC	8	.	.	.

Table 3.2: Age by sex of patient at encounter - Allopurinol Apr03-Mar04

The FREQ Procedure

Table of SEX by AGEGP

SEX(Sex of patient)		AGEGP(Age-group)					
Frequency	Percent	15-24	25-44	45-64	65-74	75+	Total
Row Pct	Col Pct						
Male	2	33	124	60	64	283	
	0.57	9.43	35.43	17.14	18.29	80.86	
	0.71	11.66	43.82	21.20	22.61		
	100.00	91.67	86.71	73.17	73.56		
Female	0	3	19	22	23	67	
	0.00	0.86	5.43	6.29	6.57	19.14	
	0.00	4.48	28.36	32.84	34.33		
	0.00	8.33	13.29	26.83	26.44		
Total	2	36	143	82	87	350	
	0.57	10.29	40.86	23.43	24.86	100.00	

Frequency Missing = 5

BEACH Survey Report - Analysis date: 03NOV08

Table 3.3: Reasons for encounters (RFEs)- ICPC chapter - Allopurinol Apr03-Mar04

RFE chapter	n	% of total RFEs	Per 100 Allopurinol encs	Lower 95% CI	Upper 95% CI
General & unspecified	223	34.84	62.82	55.1	70.5
Endocrine & metabolic	112	17.50	31.55	25.4	37.7
Circulatory	97	15.16	27.32	22.2	32.5
Musculoskeletal	66	10.31	18.59	14.1	23.1
Skin	36	5.63	10.14	6.2	14.1
Respiratory	31	4.84	8.73	5.6	11.9
Digestive	29	4.53	8.17	4.7	11.6
Psychological	10	1.56	2.82	0.9	4.7
Urology	10	1.56	2.82	1.1	4.5
Blood	6	0.94	1.69	0.3	3.0
Neurological	6	0.94	1.69	0.2	3.2
Eye	5	0.78	1.41	0.2	2.6
Male genital system	4	0.63	1.13	0.0	2.2
Ear	3	0.47	0.85	0.0	1.8
Social	2	0.31	0.56	.	.
.
Subtotal	640	100.00	.	.	.
.
Total RFEs	640	100.00	180.28	171.6	189.0

BEACH Survey Report - Analysis date: 03NOV08

Table 3.4: Most frequent patient reasons for encounters (RFEs) - Allopurinol Apr03-Mar04

RFE label	n	% of total RFEs	Per 100 Allopurinol encs	Lower 95% CI	Upper 95% CI
Prescription all*	176	27.50	49.58	43.1	56.0
Gout	56	8.75	15.77	11.1	20.5
Cardiac check-up*	45	7.03	12.68	8.9	16.4
Hypertension*	22	3.44	6.20	3.7	8.7
Test results*	22	3.44	6.20	3.6	8.8
General check-up*	19	2.97	5.35	3.0	7.7
Preventive immun/vacc/meds-all*	14	2.19	3.94	1.9	6.0
Foot/toe symptom/complaint	14	2.19	3.94	1.9	6.0
Blood test NOS	10	1.56	2.82	0.9	4.7
Knee symptom/complaint	10	1.56	2.82	1.0	4.7
Endocrinology check-up*	8	1.25	2.25	0.5	4.0
Joint symptom/complaint NOS	8	1.25	2.25	0.5	4.0
Clarify/discuss patient rfe/demand NOS	7	1.09	1.97	0.5	3.4
Administrative procedure NOS	7	1.09	1.97	0.5	3.4
Follow-up encounter unspecified endocrine/metabol	7	1.09	1.97	0.5	3.4
Follow-up encounter unspecified NOS	6	0.94	1.69	0.4	3.0
Swelling*	6	0.94	1.69	0.2	3.2
Cough	6	0.94	1.69	0.4	3.0
Nausea	5	0.78	1.41	0.0	2.8
Arthritis*	5	0.78	1.41	0.2	2.6
Skin symptom/complaint, other	5	0.78	1.41	0.2	2.6
Other reason for encounter NEC NOS	4	0.63	1.13	0.0	2.2
Back complaint*	4	0.63	1.13	0.0	2.2
Hand/finger symptom/complaint	4	0.63	1.13	0.0	2.2
Sleep disturbance	4	0.63	1.13	0.0	2.2
Urinary disease, other	4	0.63	1.13	0.0	2.2
Weakness/tiredness general	3	0.47	0.85	0.0	1.8
Other referrals NEC NOS	3	0.47	0.85	0.0	1.8
Blood test blood/lymph	3	0.47	0.85	0.0	1.8
Oesophagus disease	3	0.47	0.85	0.0	1.8
.
Subtotal	490	76.56	.	.	.
.
Other RFEs	150	23.44	.	.	.
.

* Includes multiple ICPC-2 or ICPC-2 PLUS codes (see Appendix 5, <www.aihw.gov.au/pubilcations/index.cfm/subject/19>).

BEACH Survey Report - Analysis date: 03NOV08

Table 3.4: Most frequent patient reasons for encounters (RFEs) - Allopurinol Apr03-Mar04

RFE label	n	% of total RFEs	Per 100 Allopurinol encs	Lower 95% CI	Upper 95% CI
Total RFEs	640	100.00	180.28	171.6	189.0

* Includes multiple ICPC-2 or ICPC-2 PLUS codes (see Appendix 5, <www.aihw.gov.au/pubilcations/index.cfm/subject/19>).

BEACH Survey Report - Analysis date: 03NOV08

Table 4.1: Medication source - Allopurinol Apr03-Mar04

Generic	Product	n	% of Allopurinol	Lower 95% CI	Upper 95% CI	Prescribed n	% of specific meds	Advised n	% of specific meds	GP supplied n	% of specific meds
Total Allopurinol		356	100.0	.	.	351	98.6	.	.	5	1.4
Allopurinol		356	100.0	100.0	100.0	351	98.6	.	.	5	1.4
	Allopurinol NOS	41	11.5	8.0	15.0	40	97.6	.	.	1	2.4
	Allopurinol capsules 100 mg	2	0.6	.	.	2	100.0
	Allopurinol capsules 300 mg	9	2.5	0.7	4.3	9	100.0
	Allopurinol tablets 100 mg	5	1.4	0.2	2.6	5	100.0
	Allopurinol tablets 300 mg	8	2.2	0.4	4.1	7	87.5	.	.	1	12.5
	Progout NOS	4	1.1	0.0	2.2	4	100.0
	Progout tablets 100 mg	20	5.6	3.1	8.1	20	100.0
	Progout tablets 300 mg	58	16.3	12.5	20.1	58	100.0
	Zyloprim NOS	3	0.8	0.0	1.8	3	100.0
	Zyloprim tablets 100 mg	64	18.0	13.7	22.2	64	100.0
	Zyloprim tablets 300 mg	142	39.9	34.3	45.5	139	97.9	.	.	3	2.1

BEACH Survey Report - Analysis date: 03NOV08

Table 4.2: Medication status - Allopurinol Apr03-Mar04

Generic	Product	n	% of Allopurinol	% of generic	New n	% of specific meds	Continued n	% of specific meds
Total Allopurinol		356	100.0	.	48	13.5	308	86.5
Allopurinol		356	100.0	.	48	13.5	308	86.5
	Allopurinol NOS	41	11.5	11.52	9	22.0	32	78.0
	Allopurinol capsules 100 mg	2	0.6	0.56	.	.	2	100.0
	Allopurinol capsules 300 mg	9	2.5	2.53	1	11.1	8	88.9
	Allopurinol tablets 100 mg	5	1.4	1.40	1	20.0	4	80.0
	Allopurinol tablets 300 mg	8	2.2	2.25	1	12.5	7	87.5
	Progout NOS	4	1.1	1.12	1	25.0	3	75.0
	Progout tablets 100 mg	20	5.6	5.62	2	10.0	18	90.0
	Progout tablets 300 mg	58	16.3	16.29	4	6.9	54	93.1
	Zyloprim NOS	3	0.8	0.84	.	.	3	100.0
	Zyloprim tablets 100 mg	64	18.0	17.98	18	28.1	46	71.9
	Zyloprim tablets 300 mg	142	39.9	39.89	11	7.7	131	92.3

Note: The 'continued' medications include medications specified as 'continued' and medications with missing status, assumed to be 'continued'.

BEACH Survey Report - Analysis date: 03NOV08

Table 4.3.1 : Prescribed regimen* - Allopurinol (generic level) Apr03-Mar04

Generic	n	Dose	Units	Quantity	Frequency	% of generic group
Allopurinol	6	.		.		1.7
Allopurinol	4	.		1	daily	1.1
Allopurinol	1	0.5	mg	.	prn	0.3
Allopurinol	1	15.0	mg	1	daily	0.3
Allopurinol	4	50.0	mg	1	daily	1.1
Allopurinol	1	75.0	mg	1	daily	0.3
Allopurinol	1	100.0	mg	.	prn	0.3
Allopurinol	75	100.0	mg	1	daily	21.1
Allopurinol	10	100.0	mg	2	daily	2.8
Allopurinol	8	150.0	mg	1	daily	2.2
Allopurinol	1	200.0	mg	.		0.3
Allopurinol	13	200.0	mg	1	daily	3.7
Allopurinol	1	250.0	mg	1	daily	0.3
Allopurinol	2	300.0	mg	.		0.6
Allopurinol	226	300.0	mg	1	daily	63.5
Allopurinol	1	500.0	mg	2	daily	0.3
Allopurinol	1	600.0	mg	1	daily	0.3

* This table includes medications prescribed, advised for over-the-counter (OTC) purchase or supplied by GPs.

BEACH Survey Report - Analysis date: 03NOV08

Table 4.3.2 : Prescribed regimen* - Allopurinol (product level) Apr03-Mar04

Product	n	Dose	Units	Quantity	Frequency	% of generic group
Allopurinol NOS	1	.		.		0.3
Allopurinol NOS	1	.		1	daily	0.3
Allopurinol NOS	1	50.0	mg	1	daily	0.3
Allopurinol NOS	1	75.0	mg	1	daily	0.3
Allopurinol NOS	12	100.0	mg	1	daily	3.4
Allopurinol NOS	1	100.0	mg	2	daily	0.3
Allopurinol NOS	1	150.0	mg	1	daily	0.3
Allopurinol NOS	1	200.0	mg	1	daily	0.3
Allopurinol NOS	1	250.0	mg	1	daily	0.3
Allopurinol NOS	21	300.0	mg	1	daily	5.9
Allopurinol capsules 100 mg	2	100.0	mg	1	daily	0.6
Allopurinol capsules 300 mg	1	.		1	daily	0.3
Allopurinol capsules 300 mg	2	150.0	mg	1	daily	0.6
Allopurinol capsules 300 mg	6	300.0	mg	1	daily	1.7
Allopurinol tablets 100 mg	1	50.0	mg	1	daily	0.3
Allopurinol tablets 100 mg	3	100.0	mg	1	daily	0.8
Allopurinol tablets 100 mg	1	200.0	mg	1	daily	0.3
Allopurinol tablets 300 mg	8	300.0	mg	1	daily	2.2
Progout NOS	1	0.5	mg	.	prn	0.3
Progout NOS	1	15.0	mg	1	daily	0.3
Progout NOS	1	300.0	mg	1	daily	0.3
Progout NOS	1	500.0	mg	2	daily	0.3
Progout tablets 100 mg	1	50.0	mg	1	daily	0.3
Progout tablets 100 mg	16	100.0	mg	1	daily	4.5
Progout tablets 100 mg	3	200.0	mg	1	daily	0.8
Progout tablets 300 mg	1	.		1	daily	0.3
Progout tablets 300 mg	1	150.0	mg	1	daily	0.3
Progout tablets 300 mg	1	300.0	mg	.		0.3
Progout tablets 300 mg	55	300.0	mg	1	daily	15.4
Zyloprim NOS	3	.		.		0.8
Zyloprim tablets 100 mg	2	.		.		0.6
Zyloprim tablets 100 mg	1	50.0	mg	1	daily	0.3
Zyloprim tablets 100 mg	1	100.0	mg	.	prn	0.3
Zyloprim tablets 100 mg	42	100.0	mg	1	daily	11.8
Zyloprim tablets 100 mg	9	100.0	mg	2	daily	2.5

* This table includes medications prescribed, advised for over-the-counter (OTC) purchase or supplied by GPs.

BEACH Survey Report - Analysis date: 03NOV08

Table 4.3.2 : Prescribed regimen* - Allopurinol (product level) Apr03-Mar04

Product	n	Dose	Units	Quantity	Frequency	% of generic group
Zyloprim tablets 100 mg	1	200	mg	.		0.3
Zyloprim tablets 100 mg	8	200	mg	1	daily	2.2
Zyloprim tablets 300 mg	1	.		1	daily	0.3
Zyloprim tablets 300 mg	4	150	mg	1	daily	1.1
Zyloprim tablets 300 mg	1	300	mg	.		0.3
Zyloprim tablets 300 mg	135	300	mg	1	daily	37.9
Zyloprim tablets 300 mg	1	600	mg	1	daily	0.3

* This table includes medications prescribed, advised for over-the-counter (OTC) purchase or supplied by GPs.

BEACH Survey Report - Analysis date: 03NOV08

Table 4.4.1 : Prescribed daily dose* - Allopurinol (generic level) Apr03-Mar04

Generic	n	Prescribed daily dose	Units	% of generic group
Allopurinol	1	15	mg	0.3
Allopurinol	4	50	mg	1.2
Allopurinol	1	75	mg	0.3
Allopurinol	75	100	mg	22.0
Allopurinol	8	150	mg	2.3
Allopurinol	23	200	mg	6.7
Allopurinol	1	250	mg	0.3
Allopurinol	226	300	mg	66.3
Allopurinol	1	600	mg	0.3
Allopurinol	1	1000	mg	0.3

*This table includes medications prescribed, advised for over-the-counter (OTC) purchase or supplied by GPs.
The calculation of prescribed daily dose (PDD) is based on those medications for which complete regimen and dosage information were recorded.

BEACH Survey Report - Analysis date: 03NOV08

Table 4.4.2 : Prescribed daily dose* - Allopurinol (product level) Apr03-Mar04

Product	n	Prescribed daily dose	Units	% of generic gorup
Allopurinol NOS	1	50	mg	0.3
Allopurinol NOS	1	75	mg	0.3
Allopurinol NOS	12	100	mg	3.5
Allopurinol NOS	1	150	mg	0.3
Allopurinol NOS	2	200	mg	0.6
Allopurinol NOS	1	250	mg	0.3
Allopurinol NOS	21	300	mg	6.2
Allopurinol capsules 100 mg	2	100	mg	0.6
Allopurinol capsules 300 mg	2	150	mg	0.6
Allopurinol capsules 300 mg	6	300	mg	1.8
Allopurinol tablets 100 mg	1	50	mg	0.3
Allopurinol tablets 100 mg	3	100	mg	0.9
Allopurinol tablets 100 mg	1	200	mg	0.3
Allopurinol tablets 300 mg	8	300	mg	2.3
Progout NOS	1	15	mg	0.3
Progout NOS	1	300	mg	0.3
Progout NOS	1	1000	mg	0.3
Progout tablets 100 mg	1	50	mg	0.3
Progout tablets 100 mg	16	100	mg	4.7
Progout tablets 100 mg	3	200	mg	0.9
Progout tablets 300 mg	1	150	mg	0.3
Progout tablets 300 mg	55	300	mg	16.1
Zyloprim tablets 100 mg	1	50	mg	0.3
Zyloprim tablets 100 mg	42	100	mg	12.3
Zyloprim tablets 100 mg	17	200	mg	5.0
Zyloprim tablets 300 mg	4	150	mg	1.2
Zyloprim tablets 300 mg	135	300	mg	39.6
Zyloprim tablets 300 mg	1	600	mg	0.3

* This table includes medications prescribed, advised for over-the-counter (OTC) purchase or supplied by GPs. The calculation of prescribed daily dose (PDD) is based on those medications for which complete regimen and dosage information were recorded.

BEACH Survey Report - Analysis date: 03NOV08

Table 4.5: Average prescribed daily dose* - Allopurinol Apr03-Mar04

Generic	Product	n	Mean	Measure	Median	Measure	Minimum	Measure	Maximum	Measure
			PDD		PDD					
Allopurinol		341.00	244.1	mg	300	mg	15	mg	1000	mg
	Allopurinol NOS	39.00	216.0	mg	300	mg	50	mg	300	mg
	Allopurinol capsules 100 mg	2.00	100.0	mg	100	mg	100	mg	100	mg
	Allopurinol capsules 300 mg	8.00	262.5	mg	300	mg	150	mg	300	mg
	Allopurinol tablets 100 mg	5.00	110.0	mg	100	mg	50	mg	200	mg
	Allopurinol tablets 300 mg	8.00	300.0	mg	300	mg	300	mg	300	mg
	Progout NOS	3.00	438.3	mg	300	mg	15	mg	1000	mg
	Progout tablets 100 mg	20.00	112.5	mg	100	mg	50	mg	200	mg
	Progout tablets 300 mg	56.00	297.3	mg	300	mg	150	mg	300	mg
	Zyloprim tablets 100 mg	60.00	127.5	mg	100	mg	50	mg	200	mg
	Zyloprim tablets 300 mg	140.00	297.9	mg	300	mg	150	mg	600	mg

* This table includes medications prescribed, advised for over-the-counter (OTC) purchase or supplied by GPs. The calculation of prescribed daily dose (PDD) is based on those medications for which complete regimen and dosage information were recorded.

BEACH Survey Report - Analysis date: 03NOV08

Table 4.6: Average number of repeats - Allopurinol Apr03-Mar04

Generic	Product	n	Mean repeats	Median repeats	Minimum	Maximum
Allopurinol		311.00	2.1	2.0	0	5
	Allopurinol NOS	35.00	1.9	2.0	0	5
	Allopurinol capsules 100 mg	1.00	2.0	2.0	2	2
	Allopurinol capsules 300 mg	9.00	2.0	2.0	2	2
	Allopurinol tablets 100 mg	4.00	1.5	2.0	0	2
	Allopurinol tablets 300 mg	8.00	2.0	2.0	2	2
	Progout NOS	4.00	1.8	1.5	1	3
	Progout tablets 100 mg	18.00	2.1	2.0	1	5
	Progout tablets 300 mg	53.00	2.2	2.0	0	5
	Zyloprim tablets 100 mg	52.00	1.8	2.0	0	5
	Zyloprim tablets 300 mg	127.00	2.3	2.0	0	5

BEACH Survey Report - Analysis date: 03NOV08

Table 5.1: Medication source - 'new' Allopurinol Apr03-Mar04

Generic	Product	n	% of 'new' Allopurinol	Lower 95% CI	Upper 95% CI	Prescribed n	% of specific meds	Advised n	% of specific meds	GP supplied n	% of specific meds
Total Allopurinol		48	100.0	.	.	47	97.9	.	.	1	2.1
Allopurinol		48	100.0	100.0	100.0	47	97.9	.	.	1	2.1
	Allopurinol NOS	9	18.8	7.2	30.3	9	100.0
	Allopurinol capsules 300 mg	1	2.1	.	.	1	100.0
	Allopurinol tablets 100 mg	1	2.1	.	.	1	100.0
	Allopurinol tablets 300 mg	1	2.1	.	.	1	100.0
	Progout NOS	1	2.1	.	.	1	100.0
	Progout tablets 100 mg	2	4.2	.	.	2	100.0
	Progout tablets 300 mg	4	8.3	0.2	16.5	4	100.0
	Zyloprim tablets 100 mg	18	37.5	23.4	51.6	18	100.0
	Zyloprim tablets 300 mg	11	22.9	10.7	35.1	10	90.9	.	.	1	9.1

BEACH Survey Report - Analysis date: 03NOV08

Table 5.2: Medication status - 'new' Allopurinol Apr03-Mar04

Generic	Product	n	% of 'new' Allopurinol	% of generic		New n	% of specific meds	Continued n	% of specific meds
Total Allopurinol		48	100.0	.		48	100	.	.
Allopurinol		48	100.0	.		48	100	.	.
	Allopurinol NOS	9	18.8	18.75		9	100	.	.
	Allopurinol capsules 300 mg	1	2.1	2.08		1	100	.	.
	Allopurinol tablets 100 mg	1	2.1	2.08		1	100	.	.
	Allopurinol tablets 300 mg	1	2.1	2.08		1	100	.	.
	Progout NOS	1	2.1	2.08		1	100	.	.
	Progout tablets 100 mg	2	4.2	4.17		2	100	.	.
	Progout tablets 300 mg	4	8.3	8.33		4	100	.	.
	Zyloprim tablets 100 mg	18	37.5	37.50		18	100	.	.
	Zyloprim tablets 300 mg	11	22.9	22.92		11	100	.	.

Note: The 'continued' medications include medications specified as 'continued' and medications with missing status, assumed to be 'continued'.

BEACH Survey Report - Analysis date: 03NOV08

Table 5.3.1 : Prescribed regimen* - 'new' Allopurinol (generic level) Apr03-Mar04

Generic	n	Dose	Units	Quantity	Frequency	% of generic group
Allopurinol	1	0.5	mg	.	prn	2.1
Allopurinol	2	50.0	mg	1	daily	4.2
Allopurinol	21	100.0	mg	1	daily	43.8
Allopurinol	4	100.0	mg	2	daily	8.3
Allopurinol	1	150.0	mg	1	daily	2.1
Allopurinol	1	200.0	mg	1	daily	2.1
Allopurinol	18	300.0	mg	1	daily	37.5

* This table includes medications prescribed, advised for over-the-counter (OTC) purchase or supplied by GPs.

BEACH Survey Report - Analysis date: 03NOV08

Table 5.3.2 : Prescribed regimen* - 'new' Allopurinol (product level) Apr03-Mar04

Product	n	Dose	Units	Quantity	Frequency	% of generic group
Allopurinol NOS	1	50.0	mg	1	daily	2.1
Allopurinol NOS	6	100.0	mg	1	daily	12.5
Allopurinol NOS	2	300.0	mg	1	daily	4.2
Allopurinol capsules 300 mg	1	300.0	mg	1	daily	2.1
Allopurinol tablets 100 mg	1	50.0	mg	1	daily	2.1
Allopurinol tablets 300 mg	1	300.0	mg	1	daily	2.1
Progout NOS	1	0.5	mg	.	prn	2.1
Progout tablets 100 mg	2	100.0	mg	1	daily	4.2
Progout tablets 300 mg	4	300.0	mg	1	daily	8.3
Zyloprim tablets 100 mg	13	100.0	mg	1	daily	27.1
Zyloprim tablets 100 mg	4	100.0	mg	2	daily	8.3
Zyloprim tablets 100 mg	1	200.0	mg	1	daily	2.1
Zyloprim tablets 300 mg	1	150.0	mg	1	daily	2.1
Zyloprim tablets 300 mg	10	300.0	mg	1	daily	20.8

* This table includes medications prescribed, advised for over-the-counter (OTC) purchase or supplied by GPs.

BEACH Survey Report - Analysis date: 03NOV08

Table 5.4.1 : Prescribed daily dose* - 'new' Allopurinol (generic level) Apr03-Mar04

Generic	n	Prescribed daily dose	Units	% of generic group
Allopurinol	2	50	mg	4.3
Allopurinol	21	100	mg	44.7
Allopurinol	1	150	mg	2.1
Allopurinol	5	200	mg	10.6
Allopurinol	18	300	mg	38.3

*This table includes medications prescribed, advised for over-the-counter (OTC) purchase or supplied by GPs.
The calculation of prescribed daily dose (PDD) is based on those medications for which complete regimen and dosage information were recorded.

BEACH Survey Report - Analysis date: 03NOV08

Table 5.4.2 : Prescribed daily dose* - 'new' Allopurinol (product level) Apr03-Mar04

Product	n	Prescribed daily dose	Units	% of generic gorup
Allopurinol NOS	1	50	mg	2.1
Allopurinol NOS	6	100	mg	12.8
Allopurinol NOS	2	300	mg	4.3
Allopurinol capsules 300 mg	1	300	mg	2.1
Allopurinol tablets 100 mg	1	50	mg	2.1
Allopurinol tablets 300 mg	1	300	mg	2.1
Progout tablets 100 mg	2	100	mg	4.3
Progout tablets 300 mg	4	300	mg	8.5
Zyloprim tablets 100 mg	13	100	mg	27.7
Zyloprim tablets 100 mg	5	200	mg	10.6
Zyloprim tablets 300 mg	1	150	mg	2.1
Zyloprim tablets 300 mg	10	300	mg	21.3

* This table includes medications prescribed, advised for over-the-counter (OTC) purchase or supplied by GPs. The calculation of prescribed daily dose (PDD) is based on those medications for which complete regimen and dosage information were recorded.

BEACH Survey Report - Analysis date: 03NOV08

Table 5.5: Average prescribed daily dose* - 'new' Allopurinol Apr03-Mar04

Generic	Product	n	Mean	Measure	Median	Measure	Minimum	Measure	Maximum	Measure
			PDD		PDD					
Allopurinol		47.00	186.2	mg	150	mg	50	mg	300	mg
	Allopurinol NOS	9.00	138.9	mg	100	mg	50	mg	300	mg
	Allopurinol capsules 300 mg	1.00	300.0	mg	300	mg	300	mg	300	mg
	Allopurinol tablets 100 mg	1.00	50.0	mg	50	mg	50	mg	50	mg
	Allopurinol tablets 300 mg	1.00	300.0	mg	300	mg	300	mg	300	mg
	Progout tablets 100 mg	2.00	100.0	mg	100	mg	100	mg	100	mg
	Progout tablets 300 mg	4.00	300.0	mg	300	mg	300	mg	300	mg
	Zyloprim tablets 100 mg	18.00	127.8	mg	100	mg	100	mg	200	mg
	Zyloprim tablets 300 mg	11.00	286.4	mg	300	mg	150	mg	300	mg

* This table includes medications prescribed, advised for over-the-counter (OTC) purchase or supplied by GPs. The calculation of prescribed daily dose (PDD) is based on those medications for which complete regimen and dosage information were recorded.

BEACH Survey Report - Analysis date: 03NOV08

Table 5.6: Average number of repeats - 'new' Allopurinol Apr03-Mar04

Generic	Product	n	Mean repeats	Median repeats	Minimum	Maximum
Allopurinol		45.00	1.8	2	0	5
	Allopurinol NOS	9.00	1.0	0	0	3
	Allopurinol capsules 300 mg	1.00	2.0	2	2	2
	Allopurinol tablets 100 mg	1.00	2.0	2	2	2
	Allopurinol tablets 300 mg	1.00	2.0	2	2	2
	Progout NOS	1.00	1.0	1	1	1
	Progout tablets 100 mg	2.00	2.0	2	2	2
	Progout tablets 300 mg	3.00	2.0	2	2	2
	Zyloprim tablets 100 mg	18.00	1.6	1	0	5
	Zyloprim tablets 300 mg	9.00	2.8	2	2	5

BEACH Survey Report - Analysis date: 03NOV08

Table 6.1: Medication source - 'continued' Allopurinol Apr03-Mar04

Generic	Product	n	% of 'continued' Allopurinol	Lower 95% CI	Upper 95% CI	Prescribed n	% of specific meds	Advised n	% of specific meds	GP supplied n	% of specific meds
Total Allopurinol		308	100.0	.	.	304	98.7	.	.	4	1.3
Allopurinol		308	100.0	100.0	100.0	304	98.7	.	.	4	1.3
	Allopurinol NOS	32	10.4	6.7	14.1	31	96.9	.	.	1	3.1
	Allopurinol capsules 100 mg	2	0.6	.	.	2	100.0
	Allopurinol capsules 300 mg	8	2.6	0.6	4.6	8	100.0
	Allopurinol tablets 100 mg	4	1.3	0.0	2.6	4	100.0
	Allopurinol tablets 300 mg	7	2.3	0.4	4.2	6	85.7	.	.	1	14.3
	Progout NOS	3	1.0	0.0	2.1	3	100.0
	Progout tablets 100 mg	18	5.8	3.2	8.5	18	100.0
	Progout tablets 300 mg	54	17.5	13.3	21.8	54	100.0
	Zyloprim NOS	3	1.0	0.0	2.1	3	100.0
	Zyloprim tablets 100 mg	46	14.9	10.6	19.2	46	100.0
	Zyloprim tablets 300 mg	131	42.5	36.5	48.6	129	98.5	.	.	2	1.5

BEACH Survey Report - Analysis date: 03NOV08

Table 6.2: Medication status - 'continued' Allopurinol Apr03-Mar04

Generic	Product	n	% of 'continued' Allopurinol	% of generic	New n	% of specific meds	Continued n	% of specific meds
Total Allopurinol		308	100.0	.	.	.	308	100
Allopurinol		308	100.0	.	.	.	308	100
	Allopurinol NOS	32	10.4	10.39	.	.	32	100
	Allopurinol capsules 100 mg	2	0.6	0.65	.	.	2	100
	Allopurinol capsules 300 mg	8	2.6	2.60	.	.	8	100
	Allopurinol tablets 100 mg	4	1.3	1.30	.	.	4	100
	Allopurinol tablets 300 mg	7	2.3	2.27	.	.	7	100
	Progout NOS	3	1.0	0.97	.	.	3	100
	Progout tablets 100 mg	18	5.8	5.84	.	.	18	100
	Progout tablets 300 mg	54	17.5	17.53	.	.	54	100
	Zyloprim NOS	3	1.0	0.97	.	.	3	100
	Zyloprim tablets 100 mg	46	14.9	14.94	.	.	46	100
	Zyloprim tablets 300 mg	131	42.5	42.53	.	.	131	100

Note: The 'continued' medications include medications specified as 'continued' and medications with missing status, assumed to be 'continued'.

BEACH Survey Report - Analysis date: 03NOV08

Table 6.3.1 : Prescribed regimen* - 'continued' Allopurinol (generic level) Apr03-Mar04

Generic	n	Dose	Units	Quantity	Frequency	% of generic group
Allopurinol	6	.		.		1.9
Allopurinol	4	.		1	daily	1.3
Allopurinol	1	15	mg	1	daily	0.3
Allopurinol	2	50	mg	1	daily	0.6
Allopurinol	1	75	mg	1	daily	0.3
Allopurinol	1	100	mg	.	prn	0.3
Allopurinol	54	100	mg	1	daily	17.5
Allopurinol	6	100	mg	2	daily	1.9
Allopurinol	7	150	mg	1	daily	2.3
Allopurinol	1	200	mg	.		0.3
Allopurinol	12	200	mg	1	daily	3.9
Allopurinol	1	250	mg	1	daily	0.3
Allopurinol	2	300	mg	.		0.6
Allopurinol	208	300	mg	1	daily	67.5
Allopurinol	1	500	mg	2	daily	0.3
Allopurinol	1	600	mg	1	daily	0.3

* This table includes medications prescribed, advised for over-the-counter (OTC) purchase or supplied by GPs.

BEACH Survey Report - Analysis date: 03NOV08

Table 6.3.2 : Prescribed regimen* - 'continued' Allopurinol (product level) Apr03-Mar04

Product	n	Dose	Units	Quantity	Frequency	% of generic group
Allopurinol NOS	1	.		.		0.3
Allopurinol NOS	1	.		1	daily	0.3
Allopurinol NOS	1	75	mg	1	daily	0.3
Allopurinol NOS	6	100	mg	1	daily	1.9
Allopurinol NOS	1	100	mg	2	daily	0.3
Allopurinol NOS	1	150	mg	1	daily	0.3
Allopurinol NOS	1	200	mg	1	daily	0.3
Allopurinol NOS	1	250	mg	1	daily	0.3
Allopurinol NOS	19	300	mg	1	daily	6.2
Allopurinol capsules 100 mg	2	100	mg	1	daily	0.6
Allopurinol capsules 300 mg	1	.		1	daily	0.3
Allopurinol capsules 300 mg	2	150	mg	1	daily	0.6
Allopurinol capsules 300 mg	5	300	mg	1	daily	1.6
Allopurinol tablets 100 mg	3	100	mg	1	daily	1.0
Allopurinol tablets 100 mg	1	200	mg	1	daily	0.3
Allopurinol tablets 300 mg	7	300	mg	1	daily	2.3
Progout NOS	1	15	mg	1	daily	0.3
Progout NOS	1	300	mg	1	daily	0.3
Progout NOS	1	500	mg	2	daily	0.3
Progout tablets 100 mg	1	50	mg	1	daily	0.3
Progout tablets 100 mg	14	100	mg	1	daily	4.5
Progout tablets 100 mg	3	200	mg	1	daily	1.0
Progout tablets 300 mg	1	.		1	daily	0.3
Progout tablets 300 mg	1	150	mg	1	daily	0.3
Progout tablets 300 mg	1	300	mg	.		0.3
Progout tablets 300 mg	51	300	mg	1	daily	16.6
Zyloprim NOS	3	.		.		1.0
Zyloprim tablets 100 mg	2	.		.		0.6
Zyloprim tablets 100 mg	1	50	mg	1	daily	0.3
Zyloprim tablets 100 mg	1	100	mg	.	prn	0.3
Zyloprim tablets 100 mg	29	100	mg	1	daily	9.4
Zyloprim tablets 100 mg	5	100	mg	2	daily	1.6
Zyloprim tablets 100 mg	1	200	mg	.		0.3
Zyloprim tablets 100 mg	7	200	mg	1	daily	2.3
Zyloprim tablets 300 mg	1	.		1	daily	0.3

* This table includes medications prescribed, advised for over-the-counter (OTC) purchase or supplied by GPs.

BEACH Survey Report - Analysis date: 03NOV08

Table 6.3.2 : Prescribed regimen* - 'continued' Allopurinol (product level) Apr03-Mar04

Product	n	Dose	Units	Quantity	Frequency	% of generic group
Zyloprim tablets 300 mg	3	150	mg	1	daily	1.0
Zyloprim tablets 300 mg	1	300	mg	.		0.3
Zyloprim tablets 300 mg	125	300	mg	1	daily	40.6
Zyloprim tablets 300 mg	1	600	mg	1	daily	0.3

* This table includes medications prescribed, advised for over-the-counter (OTC) purchase or supplied by GPs.

BEACH Survey Report - Analysis date: 03NOV08

Table 6.4.1 : Prescribed daily dose* - 'continued' Allopurinol (generic level) Apr03-Mar04

Generic	n	Prescribed daily dose	Units	% of generic group
Allopurinol	1	15	mg	0.3
Allopurinol	2	50	mg	0.7
Allopurinol	1	75	mg	0.3
Allopurinol	54	100	mg	18.4
Allopurinol	7	150	mg	2.4
Allopurinol	18	200	mg	6.1
Allopurinol	1	250	mg	0.3
Allopurinol	208	300	mg	70.7
Allopurinol	1	600	mg	0.3
Allopurinol	1	1000	mg	0.3

*This table includes medications prescribed, advised for over-the-counter (OTC) purchase or supplied by GPs.
The calculation of prescribed daily dose (PDD) is based on those medications for which complete regimen
and dosage information were recorded.

BEACH Survey Report - Analysis date: 03NOV08

Table 6.4.2 : Prescribed daily dose* - 'continued' Allopurinol (product level) Apr03-Mar04

Product	n	Prescribed daily dose	Units	% of generic gorup
Allopurinol NOS	1	75	mg	0.3
Allopurinol NOS	6	100	mg	2.0
Allopurinol NOS	1	150	mg	0.3
Allopurinol NOS	2	200	mg	0.7
Allopurinol NOS	1	250	mg	0.3
Allopurinol NOS	19	300	mg	6.5
Allopurinol capsules 100 mg	2	100	mg	0.7
Allopurinol capsules 300 mg	2	150	mg	0.7
Allopurinol capsules 300 mg	5	300	mg	1.7
Allopurinol tablets 100 mg	3	100	mg	1.0
Allopurinol tablets 100 mg	1	200	mg	0.3
Allopurinol tablets 300 mg	7	300	mg	2.4
Progout NOS	1	15	mg	0.3
Progout NOS	1	300	mg	0.3
Progout NOS	1	1000	mg	0.3
Progout tablets 100 mg	1	50	mg	0.3
Progout tablets 100 mg	14	100	mg	4.8
Progout tablets 100 mg	3	200	mg	1.0
Progout tablets 300 mg	1	150	mg	0.3
Progout tablets 300 mg	51	300	mg	17.3
Zyloprim tablets 100 mg	1	50	mg	0.3
Zyloprim tablets 100 mg	29	100	mg	9.9
Zyloprim tablets 100 mg	12	200	mg	4.1
Zyloprim tablets 300 mg	3	150	mg	1.0
Zyloprim tablets 300 mg	125	300	mg	42.5
Zyloprim tablets 300 mg	1	600	mg	0.3

* This table includes medications prescribed, advised for over-the-counter (OTC) purchase or supplied by GPs. The calculation of prescribed daily dose (PDD) is based on those medications for which complete regimen and dosage information were recorded.

BEACH Survey Report - Analysis date: 03NOV08

Table 6.5: Average prescribed daily dose* - 'continued' Allopurinol Apr03-Mar04

Generic	Product	n	Mean	Measure	Median	Measure	Minimum	Measure	Maximum	Measure
			PDD		PDD					
Allopurinol		294.00	253.4	mg	300	mg	15	mg	1000	mg
	Allopurinol NOS	30.00	239.2	mg	300	mg	75	mg	300	mg
Allopurinol	capsules 100 mg	2.00	100.0	mg	100	mg	100	mg	100	mg
Allopurinol	capsules 300 mg	7.00	257.1	mg	300	mg	150	mg	300	mg
Allopurinol	tablets 100 mg	4.00	125.0	mg	100	mg	100	mg	200	mg
Allopurinol	tablets 300 mg	7.00	300.0	mg	300	mg	300	mg	300	mg
	Progout NOS	3.00	438.3	mg	300	mg	15	mg	1000	mg
	Progout tablets 100 mg	18.00	113.9	mg	100	mg	50	mg	200	mg
	Progout tablets 300 mg	52.00	297.1	mg	300	mg	150	mg	300	mg
Zyloprim	tablets 100 mg	42.00	127.4	mg	100	mg	50	mg	200	mg
Zyloprim	tablets 300 mg	129.00	298.8	mg	300	mg	150	mg	600	mg

* This table includes medications prescribed, advised for over-the-counter (OTC) purchase or supplied by GPs. The calculation of prescribed daily dose (PDD) is based on those medications for which complete regimen and dosage information were recorded.

BEACH Survey Report - Analysis date: 03NOV08

Table 6.6: Average number of repeats - 'continued' Allopurinol Apr03-Mar04

Generic	Product	n	Mean repeats	Median repeats	Minimum	Maximum
Allopurinol		266.00	2.2	2	0	5
	Allopurinol NOS	26.00	2.2	2	0	5
	Allopurinol capsules 100 mg	1.00	2.0	2	2	2
	Allopurinol capsules 300 mg	8.00	2.0	2	2	2
	Allopurinol tablets 100 mg	3.00	1.3	2	0	2
	Allopurinol tablets 300 mg	7.00	2.0	2	2	2
	Progout NOS	3.00	2.0	2	1	3
	Progout tablets 100 mg	16.00	2.1	2	1	5
	Progout tablets 300 mg	50.00	2.2	2	0	5
	Zyloprim tablets 100 mg	34.00	1.9	2	0	5
	Zyloprim tablets 300 mg	118.00	2.3	2	0	5

BEACH Survey Report - Analysis date: 03NOV08

Table 7.1.1: Problems managed- ICPC chapter - Allopurinol Apr03-Mar04

Problem label	n probs	% of GPs*	% of Allopurinol problems	Lower 95% CI	Upper 95% CI	% of specific problem**
Endocrine & metabolic	279	21.9	78.59	73.68	83.50	2.41
General & unspecified	41	3.3	11.55	7.56	15.54	0.26
Urology	12	1.1	3.38	1.34	5.42	0.39
Circulatory	10	1.0	2.82	1.10	4.53	0.06
Musculoskeletal	9	0.7	2.54	0.44	4.63	0.05
Blood	4	0.4	1.13	0.02	2.23	0.23
.
Total problems	355	.	100.00	.	.	.

* The Proportion of all GPs within the data period prescribed, advised or supplied at least one selected medication to manage the specific problem.
 ** Proportion of specific problem managed with at least one selected medication at the encounter.

BEACH Survey Report - Analysis date: 03NOV08

Table 7.1.2: Problems managed - Allopurinol Apr03-Mar04

Problem label	n probs	% of GPs**	% of Allopurinol problems	Lower 95% CI	Upper 95% CI	% of specific problem***
Gout	269	21.0	75.77	70.57	80.98	46.06
Prescription all*	25	2.3	7.04	4.15	9.93	1.10
Abnormal test results*	20	1.5	5.63	2.62	8.65	2.29
Hypertension*	9	0.9	2.54	0.91	4.16	0.10
Arthritis*	5	0.4	1.41	0.00	2.85	0.66
Urinary disease, other	4	0.3	1.13	0.00	2.47	1.26
Test results*	3	0.3	0.85	0.00	1.81	0.23
Urinary calculus	3	0.3	0.85	0.00	1.81	3.49
Other preventive proced endocrine/metabolic	2	0.2	0.56	.	.	100.00
Risk factor NOS	1	0.1	0.28	.	.	0.24
Observation/health educat/advice/diet NOS	1	0.1	0.28	.	.	0.20
Leukaemia	1	0.1	0.28	.	.	1.59
Malignant neoplasm blood, other	1	0.1	0.28	.	.	1.54
Purpura/coagulation defect	1	0.1	0.28	.	.	1.10
Back complaint*	1	0.1	0.28	.	.	0.04
General check-up*	1	0.1	0.28	.	.	0.05
Osteoarthritis*	1	0.1	0.28	.	.	0.04
Lipid disorders*	1	0.1	0.28	.	.	0.03
Foot/toe symptom/complaint	1	0.1	0.28	.	.	0.67
Endocrine/metab/nutrition symptom/complaint, other	1	0.1	0.28	.	.	0.48
Obesity (BMI > 30)	1	0.1	0.28	.	.	0.14
Urine symptom/complaint, other	1	0.1	0.28	.	.	7.14
Urinary symptom/complaint, other	1	0.1	0.28	.	.	4.76
Excise/remov tissue/biopsy/destruct/debride/cauter	1	0.1	0.28	.	.	6.25
.
Total problems	355	.	100.00	.	.	.

* Includes multiple ICPC-2 or ICPC-2 PLUS codes (see Appendix 5, <www.aihw.gov.au/pubilcations/index.cfm/subject/19>).

** The Proportion of all GPs within the data period prescribed, advised or supplied at least one selected medication to manage the specific problem.

*** Poportion of specific problem managed with at least one selected medication at the encounter.

Table 7.2: Medication source by individual problem managed - Allopurinol Apr03-Mar04

Problem managed	n meds**	% of Allopurinol	Prescribed n	% of meds for specific prob	Advised n	% of meds for specific prob	GP supplied n	% of meds for specific prob
Gout	270	75.8	266	98.5	.	.	4	1.5
Prescription all*	25	7.0	25	100.0
Abnormal test results*	20	5.6	20	100.0
Hypertension*	9	2.5	9	100.0
Arthritis*	5	1.4	5	100.0
Urinary disease, other	4	1.1	4	100.0
Test results*	3	0.8	3	100.0
Urinary calculus	3	0.8	2	66.7	.	.	1	33.3
Other preventive proced endocrine/metabolic	2	0.6	2	100.0
Risk factor NOS	1	0.3	1	100.0
Observation/health educat/advice/diet NOS	1	0.3	1	100.0
Leukaemia	1	0.3	1	100.0
Malignant neoplasm blood, other	1	0.3	1	100.0
Purpura/coagulation defect	1	0.3	1	100.0
Back complaint*	1	0.3	1	100.0
General check-up*	1	0.3	1	100.0
Osteoarthritis*	1	0.3	1	100.0
Lipid disorders*	1	0.3	1	100.0
Foot/toe symptom/complaint	1	0.3	1	100.0
Endocrine/metab/nutrition symptom/complaint, other	1	0.3	1	100.0
Obesity (BMI > 30)	1	0.3	1	100.0
Urine symptom/complaint, other	1	0.3	1	100.0
Urinary symptom/complaint, other	1	0.3	1	100.0
Excise/remov tissue/biopsy/destruct/debride/cauter	1	0.3	1	100.0
	=====		=====		=====		=====	
	356		351		0		5	

* Includes multiple ICPC-2 or ICPC-2 PLUS codes (see Appendix 5, <www.aihw.gov.au/pubilcations/index.cfm/subject/19>).

** The number of selected medications prescribed, advised over the counter, or supplied by GPs for the specific problem.

Table 7.3: Medication status by individual problem managed - Allopurinol Apr03-Mar04

Problem managed	n meds**	% of Allopurinol	New n	% of meds for specific prob	Continued n	% of meds for specific prob
Gout	270	75.8	34	12.6	236	87.4
Prescription all*	25	7.0	.	.	25	100.0
Abnormal test results*	20	5.6	8	40.0	12	60.0
Hypertension*	9	2.5	.	.	9	100.0
Arthritis*	5	1.4	1	20.0	4	80.0
Urinary disease, other	4	1.1	.	.	4	100.0
Test results*	3	0.8	.	.	3	100.0
Urinary calculus	3	0.8	.	.	3	100.0
Other preventive proced endocrine/metabolic	2	0.6	.	.	2	100.0
Risk factor NOS	1	0.3	.	.	1	100.0
Observation/health educat/advice/diet NOS	1	0.3	.	.	1	100.0
Leukaemia	1	0.3	.	.	1	100.0
Malignant neoplasm blood, other	1	0.3	.	.	1	100.0
Purpura/coagulation defect	1	0.3	.	.	1	100.0
Back complaint*	1	0.3	1	100.0	.	.
General check-up*	1	0.3	.	.	1	100.0
Osteoarthritis*	1	0.3	.	.	1	100.0
Lipid disorders*	1	0.3	.	.	1	100.0
Foot/toe symptom/complaint	1	0.3	1	100.0	.	.
Endocrine/metab/nutrition symptom/complaint, other	1	0.3	.	.	1	100.0
Obesity (BMI > 30)	1	0.3	1	100.0	.	.
Urine symptom/complaint, other	1	0.3	.	.	1	100.0
Urinary symptom/complaint, other	1	0.3	1	100.0	.	.
Excise/remov tissue/biopsy/destruct/debride/cauter	1	0.3	1	100.0	.	.
	=====		===		=====	
	356		48		308	

* Includes multiple ICPC-2 or ICPC-2 PLUS codes (see Appendix 5, <www.aihw.gov.au/pubilcations/index.cfm/subject/19>).

** The number of selected medications prescribed, advised over the counter, or supplied by GPs for the specific problem.

BEACH Survey Report - Analysis date: 03NOV08

Table 7.4: Prescribed regimen** by individual problem managed for each generic
- Allopurinol Apr03-Mar04

Generic	Problem label	n meds	Dose	Units	Quantity	Frequency	% of generic group
Allopurinol	Risk factor NOS	1	300.0	mg	1	daily	0.28
	Observation/health educat/advice/diet NOS	1	300.0	mg	1	daily	0.28
	Leukaemia	1	300.0	mg	1	daily	0.28
	Malignant neoplasm blood, other	1	100.0	mg	1	daily	0.28
	Purpura/coagulation defect	1	100.0	mg	1	daily	0.28
	Arthritis*	1	0.28
	Arthritis*	2	100.0	mg	1	daily	0.56
	Arthritis*	2	300.0	mg	1	daily	0.56
	Back complaint*	1	300.0	mg	1	daily	0.28
	General check-up*	1	300.0	mg	1	daily	0.28
	Hypertension*	2	100.0	mg	1	daily	0.56
	Hypertension*	1	200.0	mg	1	daily	0.28
	Hypertension*	6	300.0	mg	1	daily	1.69
	Osteoarthritis*	1	100.0	mg	1	daily	0.28
	Prescription all*	2	.	.	1	daily	0.56
	Prescription all*	1	100.0	mg	.	prn	0.28
	Prescription all*	2	100.0	mg	1	daily	0.56
	Prescription all*	1	150.0	mg	1	daily	0.28
	Prescription all*	1	200.0	mg	1	daily	0.28
	Prescription all*	18	300.0	mg	1	daily	5.06
	Test results*	1	100.0	mg	1	daily	0.28
	Test results*	1	250.0	mg	1	daily	0.28
	Test results*	1	300.0	mg	1	daily	0.28
	Abnormal test results*	6	100.0	mg	1	daily	1.69
	Abnormal test results*	1	150.0	mg	1	daily	0.28
	Abnormal test results*	13	300.0	mg	1	daily	3.65
	Lipid disorders*	1	300.0	mg	1	daily	0.28
	Foot/toe symptom/complaint	1	100.0	mg	1	daily	0.28
	Endocrine/metab/nutrition symptom/complaint, other	1	200.0	mg	1	daily	0.28
	Other preventive proced endocrine/metabolic	2	300.0	mg	1	daily	0.56
	Obesity (BMI > 30)	1	300.0	mg	1	daily	0.28
	Gout	5	1.40
	Gout	1	.	.	1	daily	0.28

* Includes multiple ICPC-2 or ICPC-2 PLUS codes (see Appendix 5, <www.aihw.gov.au/pubilcations/index.cfm/subject/19>).

** This table includes medications prescribed, advised for over-the-counter (OTC) purchase or supplied by GPs.

BEACH Survey Report - Analysis date: 03NOV08

Table 7.4: Prescribed regimen** by individual problem managed for each generic
- Allopurinol Apr03-Mar04

Generic	Problem label	n meds	Dose	Units	Quantity	Frequency	% of generic group
	Gout	1	0.5	mg	.	prn	0.28
	Gout	1	15.0	mg	1	daily	0.28
	Gout	3	50.0	mg	1	daily	0.84
	Gout	1	75.0	mg	1	daily	0.28
	Gout	55	100.0	mg	1	daily	15.45
	Gout	10	100.0	mg	2	daily	2.81
	Gout	6	150.0	mg	1	daily	1.69
	Gout	1	200.0	mg	.		0.28
	Gout	10	200.0	mg	1	daily	2.81
	Gout	2	300.0	mg	.		0.56
	Gout	172	300.0	mg	1	daily	48.31
	Gout	1	500.0	mg	2	daily	0.28
	Gout	1	600.0	mg	1	daily	0.28
	Urine symptom/complaint, other	1	300.0	mg	1	daily	0.28
	Urinary symptom/complaint, other	1	50.0	mg	1	daily	0.28
	Excise/remov tissue/biopsy/destruct/debride/cauter	1	100.0	mg	1	daily	0.28
	Urinary calculus	3	300.0	mg	1	daily	0.84
	Urinary disease, other	1	.		1	daily	0.28
	Urinary disease, other	2	100.0	mg	1	daily	0.56
	Urinary disease, other	1	300.0	mg	1	daily	0.28

* Includes multiple ICPC-2 or ICPC-2 PLUS codes (see Appendix 5, <www.aihw.gov.au/pubilcations/index.cfm/subject/19>).

** This table includes medications prescribed, advised for over-the-counter (OTC) purchase or supplied by GPs.

BEACH Survey Report - Analysis date: 03NOV08

Table 7.5: Prescribed daily dose** by individual problem managed for each generic
- Allopurinol Apr03-Mar04

Generic	Problem label	n meds	Prescribed daily dose**	Units	% of generic group
Allopurinol	Risk factor NOS	1	300	mg	0.29
	Observation/health educat/advice/diet NOS	1	300	mg	0.29
	Leukaemia	1	300	mg	0.29
	Malignant neoplasm blood, other	1	100	mg	0.29
	Purpura/coagulation defect	1	100	mg	0.29
	Arthritis*	2	100	mg	0.59
	Arthritis*	2	300	mg	0.59
	Back complaint*	1	300	mg	0.29
	General check-up*	1	300	mg	0.29
	Hypertension*	2	100	mg	0.59
	Hypertension*	1	200	mg	0.29
	Hypertension*	6	300	mg	1.76
	Osteoarthritis*	1	100	mg	0.29
	Prescription all*	2	100	mg	0.59
	Prescription all*	1	150	mg	0.29
	Prescription all*	1	200	mg	0.29
	Prescription all*	18	300	mg	5.28
	Test results*	1	100	mg	0.29
	Test results*	1	250	mg	0.29
	Test results*	1	300	mg	0.29
	Abnormal test results*	6	100	mg	1.76
	Abnormal test results*	1	150	mg	0.29
	Abnormal test results*	13	300	mg	3.81
	Lipid disorders*	1	300	mg	0.29
	Foot/toe symptom/complaint	1	100	mg	0.29
	Endocrine/metab/nutrition symptom/complaint, other	1	200	mg	0.29
	Other preventive proced endocrine/metabolic	2	300	mg	0.59
	Obesity (BMI > 30)	1	300	mg	0.29
	Gout	1	15	mg	0.29
	Gout	3	50	mg	0.88
	Gout	1	75	mg	0.29

* Includes multiple ICPC-2 or ICPC-2 PLUS codes (see Appendix 5, <www.aihw.gov.au/pubilcations/index.cfm/subject/19>).

** This table includes medications prescribed, advised for over-the-counter (OTC) purchase or supplied by GPs. The calculation of prescribed daily dose (PDD) is based on those medications for which complete regimen and dosage information were recorded.

BEACH Survey Report - Analysis date: 03NOV08

Table 7.5: Prescribed daily dose** by individual problem managed for each generic
 - Allopurinol Apr03-Mar04

Generic	Problem label	n meds	Prescribed daily dose**	Units	% of generic group
	Gout	55	100	mg	16.13
	Gout	6	150	mg	1.76
	Gout	20	200	mg	5.87
	Gout	172	300	mg	50.44
	Gout	1	600	mg	0.29
	Gout	1	1000	mg	0.29
	Urine symptom/complaint, other	1	300	mg	0.29
	Urinary symptom/complaint, other	1	50	mg	0.29
	Excise/remov tissue/biopsy/destruct/debride/cauter	1	100	mg	0.29
	Urinary calculus	3	300	mg	0.88
	Urinary disease, other	2	100	mg	0.59
	Urinary disease, other	1	300	mg	0.29

* Includes multiple ICPC-2 or ICPC-2 PLUS codes (see Appendix 5, <www.aihw.gov.au/pubilcations/index.cfm/subject/19>).

** This table includes medications prescribed, advised for over-the-counter (OTC) purchase or supplied by GPs.
 The calculation of prescribed daily dose (PDD) is based on those medications for which complete regimen and dosage information were recorded.

BEACH Survey Report - Analysis date: 03NOV08

Table 7.6: Average prescribed daily dose** by individual problem managed for each generic
- Allopurinol Apr03-Mar04

Generic	Problem label	n meds	Mean	Median		Minimum	Measure	Maximum	Measure	
			PDD	PDD	Measure					
Allopurinol	Risk factor NOS	1	300.0	mg	300	mg	300	mg	300	mg
	Observation/health educat/advice/diet NOS	1	300.0	mg	300	mg	300	mg	300	mg
	Leukaemia	1	300.0	mg	300	mg	300	mg	300	mg
	Malignant neoplasm blood, other	1	100.0	mg	100	mg	100	mg	100	mg
	Purpura/coagulation defect	1	100.0	mg	100	mg	100	mg	100	mg
	Arthritis*	4	200.0	mg	200	mg	100	mg	300	mg
	Back complaint*	1	300.0	mg	300	mg	300	mg	300	mg
	General check-up*	1	300.0	mg	300	mg	300	mg	300	mg
	Hypertension*	9	244.4	mg	300	mg	100	mg	300	mg
	Osteoarthritis*	1	100.0	mg	100	mg	100	mg	100	mg
	Prescription all*	22	270.5	mg	300	mg	100	mg	300	mg
	Test results*	3	216.7	mg	250	mg	100	mg	300	mg
	Abnormal test results*	20	232.5	mg	300	mg	100	mg	300	mg
	Lipid disorders*	1	300.0	mg	300	mg	300	mg	300	mg
	Foot/toe symptom/complaint	1	100.0	mg	100	mg	100	mg	100	mg
	Endocrine/metab/nutrition symptom/complaint, other	1	200.0	mg	200	mg	200	mg	200	mg
	Other preventive proced endocrine/metabolic	2	300.0	mg	300	mg	300	mg	300	mg
	Obesity (BMI > 30)	1	300.0	mg	300	mg	300	mg	300	mg
	Gout	260	245.5	mg	300	mg	15	mg	1000	mg
	Urine symptom/complaint, other	1	300.0	mg	300	mg	300	mg	300	mg
Urinary symptom/complaint, other	1	50.0	mg	50	mg	50	mg	50	mg	
Excise/remov tissue/biopsy/destruct/debride/cauter	1	100.0	mg	100	mg	100	mg	100	mg	
Urinary calculus	3	300.0	mg	300	mg	300	mg	300	mg	
Urinary disease, other	3	166.7	mg	100	mg	100	mg	300	mg	

* Includes multiple ICPC-2 or ICPC-2 PLUS codes (see Appendix 5, <www.aihw.gov.au/pubilcations/index.cfm/subject/19>).

** This table includes medications prescribed, advised for over-the-counter (OTC) purchase or supplied by GPs.
The calculation of prescribed daily dose (PDD) is based on those medications for which complete regimen and dosage information were recorded.

BEACH Survey Report - Analysis date: 03NOV08

Table 7.7: Average number of repeats by individual problem managed - Allopurinol Apr03-Mar04

Problem label	n meds	Mean repeats	Median repeats	Minimum	Maximum
Gout	237.00	2.2	2.0	0	5
Prescription all*	21.00	2.2	2.0	1	5
Abnormal test results*	19.00	1.7	2.0	0	5
Hypertension*	9.00	2.0	2.0	2	2
Urinary disease, other	4.00	3.5	3.5	2	5
Urinary calculus	3.00	2.0	2.0	2	2
Arthritis*	2.00	1.0	1.0	0	2
Other preventive proced endocrine/metabolic	2.00	3.5	3.5	2	5
Risk factor NOS	1.00	2.0	2.0	2	2
Observation/health educat/advice/diet NOS	1.00	0.0	0.0	0	0
Malignant neoplasm blood, other	1.00	1.0	1.0	1	1
Back complaint*	1.00	2.0	2.0	2	2
General check-up*	1.00	2.0	2.0	2	2
Osteoarthritis*	1.00	2.0	2.0	2	2
Test results*	1.00	2.0	2.0	2	2
Lipid disorders*	1.00	0.0	0.0	0	0
Foot/toe symptom/complaint	1.00	1.0	1.0	1	1
Endocrine/metab/nutrition symptom/complaint, other	1.00	2.0	2.0	2	2
Obesity (BMI > 30)	1.00	2.0	2.0	2	2
Urine symptom/complaint, other	1.00	2.0	2.0	2	2
Urinary symptom/complaint, other	1.00	2.0	2.0	2	2
Excise/remov tissue/biopsy/destruct/debride/cauter	1.00	0.0	0.0	0	0

* Includes multiple ICPC-2 or ICPC-2 PLUS codes (see Appendix 5, <www.aihw.gov.au/pubilcations/index.cfm/subject/19>).